Neural Tissue Xenotransplantation: What is Needed Prior to Clinical Trials in Parkinson's Disease?

Author:

Barker Roger A.1,Kendall A. Lisa1,Widner Håkan2,Widner H.3,Larsson L.3,Czech K. A.3,Anderson P.3,Mirza B.3,Dunnett S. B.4,Kendall A. L.4,Annett L.E.4,Barker R.4,Torres E.4,Rosser A. E.4,Watts C.4,Zimmer J.,Finsen B. R.5,Dahl-Jørgensen A.5,Pedersen E. B.5,Brevig T.5,Meyer M.5,Holgersson J.6,Korsgren O.7,Breimer M.8,Gjedde A.9,Danielsen E.9,

Affiliation:

1. Department of Experimental Psychology and Centre for Brain Repair, University of Cambridge, UK

2. Neuronal Survival Unit, Wallenberg Neuroscience Center, University of Lund, Sweden

3. Centre for Brain Repair, University of Cambridge, UK

4. Department of Anatomy and Cell Biology, Odense University, Denmark

5. Division of Clinical Immunology at Karolinska Institute at Huddinge Hospital, Sweden

6. Department of Clinical Laboratory Sciences, Division of Clinical Immunology and Transfusion Medicine, Uppsala University Hospital, Sweden

7. Department of Clinical Chemistry and Transfusion Medicine, Sahlgren University Hospital Gothenburg, Sweden

8. Positron Emission Tomography Center, Aarhus University Hospital, Denmark

9. Neurosearch A/S, Glostrup, Denmark (A. Møller).

Abstract

Embryonic allografted human tissue in patients with Parkinson's disease has been shown to survive and ameliorate many of the symptoms of this disease. Despite this success, the practical problems of using this tissue coupled to the ethical restrictions of using aborted human fetal tissue have lead to an exploration for alternative sources of suitable material for grafting, including xenogeneic embryonic dopaminergic-rich neural tissue. Nevertheless, xenografted neural tissue itself generates a number of practical, ethical, safety, and immunological issues that have to be addressed prior to any clinical xenotransplant program. In this article we review these critical issues and set out the criteria that we consider need to be met in the development of our clinical xenotransplantation research programs. We advocate that these, or similar, criteria should be adopted and made explicit by other centers contemplating similar clinical trials.

Publisher

SAGE Publications

Subject

Transplantation,Cell Biology,Biomedical Engineering

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3